Gain Therapeutics’ Post

🌟 Friday Read: Accelerating Drug Development with Spatial Biology 👉https://bit.ly/4aro6Lo Presage Biosciences, Inc.'s CIVO® platform, combined with GeoMx and CosMx technologies, effectively tracks anti-neoplastic and immune-modulating activity in the intact tumor microenvironment. This innovative approach is speeding up drug development and paving the way for more successful clinical trials.🔬 #SpatialBiology #DrugDevelopment #FridayRead This post may include information regarding CosMx™ SMI products for RNA detection, which products are not available in the Federal Republic of Germany, as further described here - https://lnkd.in/gUXh88Pr.

Recently, Argenica released results from a pilot study assessing the efficacy of ARG-007 in a ferret preclinical model of mild to moderate traumatic brain injury (modTBI). Based on the positive results shown in this study, the Company will investigate the performance of ARG-007 in a larger scale ferret preclinical study to further validate this data. Taken together with previous rodent studies, this will provide Argenica with a robust preclinical data set on the efficacy of ARG-007 in TBI. Learn more or read the full announcement ➡ https://lnkd.in/evuvHHN7 #ASX #AGN #TBI #traumaticbraininjury #biotechnology #lifesciences #ARG007

Must-Read Research! Explore how a broken heart can be healed! Scientists from UBC, Borea Therapeutics, and Aspect Biosystems have uncovered region-specific mechanisms driving #heart repair after a #heartattack using 10x Genomics #Visium, advancing #therapeutic #angiogenesis strategies. Learn more: https://zurl.co/9XPCz

#Pala #SingleCellDispenser from #biotechne: The Pala Single Cell Dispenser is your benchtop analytical partner for single cell sorting. No matter what cell type you are working with, get single cells dispensed directly into your 96- or 384-well plates, all under 7 minutes! By combining proprietary microfluidics, flow cytometry, and liquid dispensing technologies, this benchtop single cell sorter automates and simplifies single cell isolation across various applications: Cell line development,  Cell engineering,  Single cell genomics,  Monoclonal antibody development,  Synthetic biology, Rare cell isolation such as circulating tumor cells (CTCs) and circulating fetal cells (CFCs). The Pala Single Cell Dispenser is affordable, easy-to-use, very low maintenance, and requires no complicated training to operate! Check out more here and get in contact: https://lnkd.in/ep9vZA5J #biotechne #singlecell #celllinedevelopment #rarecells #cellsorting #Pala

Looking to carry out in vitro projects using microglia? Make sure to access our expertise! At Axol Bioscience, we've spent the last 10 years developing the manufacturing capabilities to become the first choice for high-quality, functionally relevant iPSC-derived microglia to power robust neuroinflammatory disease models. And with >40% of our axoServices™ projects involving microglia, we've become the experts when it comes to designing and executing microglia-based in vitro research, including well-validated phagocytosis assays using a range of baits. In this excerpt from our webinar "Modeling neuroinflammation: hiPSC-derived microglia for compound screening", Axol Scientific Group Leader Jess Tilman talks us through the phagocytosis assay data generated as part of the functional validation of our axoCells™ microglia. Click here to see the full webinar "Modeling neuroinflammation: hiPSC-derived microglia for compound screening": https://hubs.la/Q02D9GYY0 Get in touch at operations@axolbio.com to discuss how we could unlock iPSC technology for your microglia projects. #iPSCs #NeurodegenerativeDiseases #DrugDiscovery #StemCells #Microglia

Because What you're missing matters... #WYMM Comprehensive analysis of m6A methylome and transcriptome by nanopore sequencing in clear cell renal carcinoma  Correlation between m6A RNA modification and the progression of clear cell renal cell carcinoma (ccRCC) has been found, however the link between methylation and transcriptional regulation has remained elusive. Here the authors explored this link using direct RNA nanopore sequencing. They identified 5224 dysregulated genes, including four obesity-related genes which could be potential biomarkers for ccRCC. https://lnkd.in/dUpF7Gaz

Looking to carry out in vitro projects using microglia? Make sure to access our expertise! At Axol Bioscience, we've spent the last 10 years developing the manufacturing capabilities to become the first choice for high-quality, functionally relevant iPSC-derived microglia to power robust neuroinflammatory disease models. And with >40% of our axoServices™ projects involving microglia, we've become the experts when it comes to designing and executing microglia-based in vitro research, including well-validated phagocytosis assays using a range of baits. In this excerpt from our webinar "Modeling neuroinflammation: hiPSC-derived microglia for compound screening", Axol Scientific Group Leader Jess Tilman talks us through the phagocytosis assay data generated as part of the functional validation of our axoCells™ microglia. Click here to see the full webinar "Modeling neuroinflammation: hiPSC-derived microglia for compound screening": https://hubs.la/Q02D9LZ20 Get in touch at operations@axolbio.com to discuss how we could unlock iPSC technology for your microglia projects. #iPSCs #NeurodegenerativeDiseases #DrugDiscovery #StemCells #Microglia

#RNA plays a crucial role in biology and is a powerful tool in modern medicine. At Elixirgen Therapeutics, we are reimagining the power of RNA to develop various technologies for the treatment of #RareDiseases. Learn more here: https://bit.ly/3MZIFVK

One of the biggest challenges in early drug discovery is finding selective binders for drug targets. In recent publication in ACS Medicinal Chemistry Letters, Our WuXi AppTec DEL team tackled this by combining DNA-Encoded Library (DEL) technology with Machine Learning (ML) on Heme Oxygenase-1 (HO-1), an enzyme sharing high similarity with its counter target HO-2. We discovered five series of HO-1 hits with >100x selectivity over HO-2 and novel scaffolds, expanding beyond the DEL chemical space. This work expanded the capability of DEL+ML method to selectivity problem, opening new doors for selective hits finding by ML approach. It also paves the way for HO-1 inhibitors development and thus targeting HO-1 related diseases like cancer and neurodegenerative disorders. Click here for the full text: https://lnkd.in/dirVcFbX #DrugDiscovery #DEL #MachineLearning #MedicinalChemistry #Selectivity #HemeOxygenase-1

Treating retina diseases more precisely | With more than 140 million nerve cells, the #retina is a highly complex visual system, where it is challenging to treat diseases. A new study by researchers from the Biophysics group of Daniel Müller ETH Zürich and colleagues from the Roche Pharma Research and Early Development (#pRED) now present an innovative therapeutic approach. The treatment involves attaching #virus|es to nanoparticles, which are electromagnetically guided to deploy therapeutics exactly where they are needed. > https://u.ethz.ch/sEDXU